LicianPro

Aclaris Therapeutics, Inc. ·

ACRS 8-K 2026-10-27

Aclaris Therapeutics, Inc. (ACRS) 8-K dated 2026-10-27 — accession 0001104659-26-118952. This URL is the filing, not the ACRS hub.

Aclaris Therapeutics, Inc. (ACRS) is a biotechnology company listed on NASDAQ.

ACRS: SECURITIES AND EXCHANGE COMMISSION

Cached items: 2.02, 7.01, 8.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported ACRS revenue for 2025-12-31 was $7.8M. Net income was -$64.9M. Revenue was down 58.2% from 2024-12-31 to 2025-12-31. ACRS currently screens at market cap $615.9M.

Not investment advice. The ACRS SEC hub lists recent forms. The stock page is the research view.

Guidance
expects to provide an update regarding plans for the potential development of ATI-052 in an additional indication in the near t

Why it matters

Source on EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr